Back to search
FDAFDA · Food and drugs·Recall number D-1436-2014

Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58

Published July 23, 2014 · Recall initiated: June 17, 2014

Summary

FDA records drug Class III recall D-1436-2014, published July 23, 2014 and initiated June 17, 2014. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 1104 blister packs; Lot: Lot 3805324A Exp. 11/14. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: out of specification impurity test results.

What to do

Voluntary: Firm initiated · Letter

Get an email if APRI has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
APRI
Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide
Lot
Lot 3805324A Exp. 11/14
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58 recalled?

Yes. FDA published recall D-1436-2014 on July 23, 2014. Reported hazard: Failed Impurities/Degradation Specifications: out of specification impurity test results.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: APRI.